Professor Paul Workman

Aviva and Socius Chosen as Preferred Bidders for London Cancer Hub Development

(IN BRIEF) Aviva and mixed-use developer Socius have been selected as the preferred bidders for the advancement of the London…

7 months ago

The Institute of Cancer Research welcomes the approval by NICE of new type of treatment for women with advanced breast cancer

LONDON, 16-Nov-2017 — /EuropaWire/ — The Institute of Cancer Research, London, welcomes the approval by NICE of a new type of treatment for…

6 years ago

University of Sussex and The Institute of Cancer Research scientists found a number of potential targets for drugs that exploit the inherent weaknesses of cancer cells

Scientists have identified weak spots in cancer cells that could be targeted and attacked by new precision drugs. BRIGHTON, 2-3-2015…

9 years ago